β-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: An overview

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue SUPPL. 1, 2005, Pages

  Singh, Bramah N ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Antiarrhythmics; Atrial fibrillation; Carvedilol; Metoprolol; Selective versus nonselective blockers; blockers

Indexed keywords

ACEBUTOLOL; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BEVANTOLOL; BISOPROLOL; BISOPROLOL FUMARATE; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; ENDOTHELIN; ESMOLOL; FIBRINOLYTIC AGENT; IRBESARTAN; ISOPRENALINE; IVABRADINE; LABETALOL; LIDOCAINE; METOPROLOL; METOPROLOL TARTRATE; NADOLOL; OXPRENOLOL; PENBUTOLOL; PHENYTOIN; PINDOLOL; PLACEBO; PRACTOLOL; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TIMOLOL; TRANDOLAPRIL; VERAPAMIL; XAMOTEROL; ALPHA 2 ADRENERGIC RECEPTOR;

ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOSELECTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART RATE; HUMAN; INCIDENCE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS RHYTHM; SUDDEN DEATH; SURVIVAL TIME; SYMPATHETIC TONE; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SELECTIVITY; META ANALYSIS (TOPIC); RECEPTOR BINDING; RECEPTOR BLOCKING; SUDDEN CARDIAC DEATH; SURVIVAL RATE;

EID: 84993949194     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/10742484050100i402     Document Type: Review

References (60)

1. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 85:I77-I91, 1992
2. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325:618-624, 1991
3. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet 353:2001-2007, 1999
4. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353:9-13, 1999
5. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
6. Singh BN, Sarma JSM. Beta-blockers and calcium-channel blockers as antiarrhythmic drugs. In Zipes DP, Jalife J (editors): Cardiac Electrophysiology. From Cell to the Bedside. WB Saunders Company, Philadelphia, pp 903-921, 2000
7. Singh BN. Antiarrhythmic drugs. In Saksena S, Camm AJ (editors): Electrophysiological Disorders of the Heart. Elsevier Churchill Livingstone, Philadelphia, pp 705-729, 2005
8. Singh BN. Pharmacological actions of certain cardiac drugs and hormones: Focus on antiarrhythmic mechanisms. D. Phil. thesis, 1971; Hertford College & University of Oxford. England. Published also by Futura Publishing Co, Mt Kisco, NY pp 1-98, 1991
9. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39:657-667, 1970
10. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39:675-687, 1970
11. Singh BN. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 6:109-119, 1972
12. Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 87:367-382, 1974
13. Singh BN, Williams EM. Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res 29:286-295, 1971
14. Hauswirth O, Singh BN. Ionic mechanisms in heart muscle in relation to the genesis and the pharmacological control of cardiac arrhythmias. Pharmacol Rev 30:5-63, 1978
15. Hoffman BF, Bigger JT, Jr. Antiarrhythmic drugs. In DiPalma JR (editor): Drill's Pharmacology in Medicine. McGraw-Hill, New York, pp 824-852, 1991
16. Harrison DC. Is there a rational basis for the modified classification of antiarrhythmic drugs? In Morganroth J, Moore EN (editors): Cardiac Arrhythmias: New Therapeutic Drugs and Devices. Martinus Nijhoff, Boston, pp 36-48, 1985
17. Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 17:344-352, 1983
18. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions. Am J Cardiol 84:11R-19R, 1999
19. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321:406-412, 1989
20. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 22:61A-71A, 1993
21. Dorian P. Antiarrhythmic action of β-blockers: Potential mechanisms. J Cardiovasc Pharmacol Ther 10(Suppl 1):S15-S22, 2005
22. Reiter MJ. Antiarrhythmic impact of anti-ischemic, antifailure and other cardiovascular strategies. Cardiac Electrophysiol Rev 3-4:194-205, 2000
23. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212, 2002
24. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80:26L-40L, 1997
25. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: Review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 9:243-255, 2004
26. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25:1154-1161, 1995
27. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 333:77-82, 1995
28. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98:2574-2579, 1998
29. Singh BN. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 78:41-53, 1996
30. Kowey P. A review of carvedilol arrhythmia data in clinical trials. J Cardiovasc Pharmacol Ther 10(Suppl 1):S59-S68, 2005
31. Nagele H, Bohlmann M, Eck U, Petersen B, Rodiger W. Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur J Heart Fail 2:71-79, 2000
32. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57:43F-49F, 1986
33. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 123:358-367, 1995
34. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80:35J-39J, 1997
35. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001
36. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 336:1-6, 1990
37. Amiodarone Trials Meta- Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350:1417-1424, 1997
38. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 99:2268-2275, 1999
39. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107:817-823, 2003
40. Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokinetic- pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 64:192-203, 1998
41. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362:7-13, 2003
42. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. J Card Fail 9:429-443, 2003
43. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134:550-560, 2001
44. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: Systematic review and meta-regression analysis. BMJ 318:1730-1737, 1999
45. Hohnloser SH. Ventricular arrhythmias: Antiadrenergic therapy for the patient with coronary artery disease. J Cardiovasc Pharmacol Ther 10(Suppl 1):S23-S32, 2005
46. Reiffel JA. Drug and drug device therapy in heart failure patients in the post-COMET era and SCD-HeFT era. J Cardiovasc Pharmacol Ther 10(Suppl 1):S45-S58, 2005
47. Rocha RM, Silva GV, Perin EC, et al. Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: Is there a difference in the elderly? Tex Heart Inst J 30:176-179, 2003
48. Bonnemeier H, Ortak J, Tolg R, et al. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: Effects on QT dynamicity. Pacing Clin Electrophysiol 28 Suppl 1:S217-S221, 2005
49. Singh BN. Overview of trends in the control of cardiac arrhythmia: Past and future. Am J Cardiol 84:3R-10R, 1999
50. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342:913-920, 2000
51. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002
52. Dorian P, Mangat I, Pinter A, Korley V. The burden of atrial fibrillation: Should we abandon antiarrhythmic drug therapy? J Cardiovasc Pharmacol Ther 9:257-262, 2004
53. Singh BN. Pursuit of sinus rhythm in patients with atrial fibrillation: Is the effort worth it? J Cardiovasc Pharmacol Ther 9:219-221, 2004
54. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376-380, 1999
55. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 106:331-336, 2002
56. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005
57. Naccarelli GV. Atrial fibrillation: Anti-adrenergic therapy in patients. J Cardiovasc Pharmacol Ther 10(Suppl 1):S33-S44, 2005
58. Kanoupakis EM, Manios EG, Mavkaris HE, et al. Effects of carvedilol and amiodarone on persistent atrial fibrillation conversion and recurrence rates. A randomized controlled study. Eur Heart J Suppl 24:367-377, 2003
59. Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36:139-146, 2000
60. Macdonald PS, Keogh AM, Aboyoun C, et al. Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure. Heart 82:589-593, 1999